CN101322554B - Health products for reducing fat - Google Patents
Health products for reducing fat Download PDFInfo
- Publication number
- CN101322554B CN101322554B CN2008100649492A CN200810064949A CN101322554B CN 101322554 B CN101322554 B CN 101322554B CN 2008100649492 A CN2008100649492 A CN 2008100649492A CN 200810064949 A CN200810064949 A CN 200810064949A CN 101322554 B CN101322554 B CN 101322554B
- Authority
- CN
- China
- Prior art keywords
- test
- content
- weight
- tablet
- meal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A weight-losing and lipid-lowering health care product relates to a health care product. The weight-losing and lipid-lowering health care product can solve the problems of gastrointestinal functional disorders, anemia, diabetes, renal dysfunction, weight rebound phenomenon and toxic and side effects of drugs when in administration of the existing weight-losing health care products or the lipid-lowering health care products by a person. The weight-losing and lipid-lowering health care product is composed of a tablet A and a table B; wherein, the tablet A is composed of chitosan, L-carnitine, chromium picolinate, calcium pyruvate and excipients; and the tablet B is composed of mixed vitamins, mixed minerals, linolenic acid and the excipients. The weight-losing and lipid-lowering drug of the invention can reduce the body weight for 3.17 plus or minus 1.56Kg after 45 days, lower the body fat for 2.83 plus or minus 1.19Kg and significantly reduce the subcutaneous fat of other parts; the average decrease rate of cholesterol is 10.48 plus or minus 5.11 percent, the average decrease rate of triglyceride is 19.57 plus or minus 8.12 percent, the total effective rate is 52.94 percent, the effects of weight-losing and lipid-lowering are significant, the weight-losing and lipid-lowering drug has no toxicity or side effects and no weight rebound.
Description
Technical field
The present invention relates to a kind of health products.
Background technology
Along with improving constantly and the variation of people's dietary structure of human living standard, the fat and ratio of the blood fat person of exceeding standard in the crowd constantly raises.It is the main cause of disease incidences such as cardiovascular and cerebrovascular disease, diabetes, artery sclerosis that fat and blood fat exceeds standard; And the annual in the world life that seizes 1,200 ten thousand people of cardiovascular and cerebrovascular disease; Near 1/4 of the total dead population in the whole world; Have great social harm, accounted for the first place of total dead population at the dead population of China's cardiovascular and cerebrovascular, this phenomenon obviously seriously threatens human life with healthy.
At present; Though the fat-reducing that is occurred on the market and the health products of lipopenicillinase and medicine are of a great variety; But because of diet products mainly through appetite-suppressing, diuresis and cause rush down for means to reach the effect of fat-reducing; And adopting appetite inhibitor class fat-reducing medicine, the systemic side effects of its medicine is more, even some serious adverse effects take place; Adopt diuretics or cause purgatives and make it the health dehydration and lose weight but fat does not reduce.And it is bigger to take harm for a long time, gastrointestinal dysfunction, anaemia, diabetes, kidney function damage can occur and rebound phenomena is arranged, even threat to life.The many toxic side effects of existing antihyperlipidemic product can produce in various degree liver, kidney and striated muscle damage.
Summary of the invention
The present invention gastrointestinal dysfunction, anaemia, diabetes, kidney function damage, the phenomenon of body weight bounce-back and the problem of poisonous side effect of medicine occur in order to solve the eater when taking existing slimming health product or fat reducing health product, and a kind of health products for reducing fat that provides.
Health products for reducing fat is made up of 1: 1 tablet A and tablet B by mass percentage; Wherein tablet A is made up of 10.0%～20.0% chitosan, 25.0%～35.0% l-cn, 0.01%～0.06% pyridine acid chrome, 25.0%～35.0% CALCIUM PYRUVIC and the auxiliary material of surplus by weight percentage; Tablet B is made up of 4.0%～8.0% mixed vitamin, 30.0%～40.0% mixed mineral matter, 30.0%～40.0% leukotrienes and the auxiliary material of surplus by weight percentage.
Adopt double-blind study that experimenter crowd is divided into test-meal group and control group at random; The test-meal group is taken the resulting health products for reducing fat of the present invention; Control group is taken the placebo of equivalent, and two groups of experimenters are kept carrying out under equal diet and the moving condition test in 45 days, test-meal group body weight decline 3.17 ± 1.56Kg after 45 days; Body fat amount decline 2.83 ± 1.19Kg; Waistline, angulus inferior scapulae, stomach wall, anterior superior spine subcutaneous fat also obviously reduce, and test-meal group crowd is carried out blood, urine and the just measurement of routine and heart rate and blood pressure, and the clinical measurement index is all in normal range (NR); The body weight phenomenon that also can not have a rebound after the drug withdrawal, the present invention is described, and the trencherman is healthy has no adverse effects to examination.0.28 ± 1.24Kg and though the control group body weight descends, the body fat amount increases by 0.24 ± 1.36Kg.So, think that the present invention has the effect of fat-reducing according to weight losing function criterion in " health food check and assessment technique standard " (version in 2003).
The hyperlipemia crowd of complication such as no severe cardiac, liver, kidney that will be 18～65 years old the age is as the experimenter; With the crowd of the edible resulting health products for reducing fat of the present invention as the test-meal group; With the crowd of edible equivalent placebo as control group; Two groups of experimenters are kept carrying out under equal diet and the moving condition test in 45 days, and test-meal group cholesterol rate of descent is 10.48 ± 5.11% after 45 days, and the triglycerides rate of descent is 19.57 ± 8.12%; Total effective rate is 52.94%; Control group cholesterol rate of descent is 0.56 ± 4.31%, and the triglycerides rate of descent is 2.83 ± 12.77%, and total effective rate is 11.54%; Explain that the present invention has the effect of reducing blood lipid to human body.
The specific embodiment
Technical scheme of the present invention is not limited to the following cited specific embodiment, also comprises the combination in any between each specific embodiment.
The specific embodiment one: this embodiment health products for reducing fat is made up of 1: 1 tablet A and tablet B by mass percentage; Wherein tablet A is made up of 10.0%～20.0% chitosan, 25.0%～35.0% l-cn, 0.01%～0.06% pyridine acid chrome, 25.0%～35.0% CALCIUM PYRUVIC and the auxiliary material of surplus by weight percentage; Tablet B is made up of 4.0%～8.0% mixed vitamin, 30.0%～40.0% mixed mineral matter, 30.0%～40.0% leukotrienes and the auxiliary material of surplus by weight percentage.
The chitosan that adds among this embodiment tablet A is the polymer substance that has positive charge, and the superabundant fats in the human body is electronegative, thus Weight-lossing hypolipemic medicine through adding the superabundant fats in the chitosan adsorbent, and after metabolism excrete.
Adding l-cn among this embodiment tablet A mainly is as carrier LCFA to be transported to promote oxidation of fatty acids in the film outside mitochondrial membrane; Become the energy that needed by human body is wanted; Reduce fat, reduced body weight; Also strengthened the ability of cardiac muscle cell's oxidation of fat, the burden of heart, the people's that slows down aging course when promoting fatigue recovery, reduction high-intensity exercise.
Add pyridine acid chrome among this embodiment tablet A and can significantly reduce T-CHOL and triglyceride level in the high fat of blood body serum, improve hdl level.Simultaneously, pyridine acid chrome also has inhibitory action to body weight, the increase of body fat.The chromium that pyridine acid chrome contains also can be used as the active component of GTF, participates in regulating the carbohydrate and fatty metabolism of body, will help to strengthen the sensitiveness of insulin, promotes the utilization of peripheral tissues to glucose.
The CALCIUM PYRUVIC that adds among this embodiment tablet A can directly get in the body, through osmosis the aliphatic acid in the body (mainly being long chain type) oxidizing fire is fallen, and makes fat reduce (consuming 48% fat at least), body weight decline.CALCIUM PYRUVIC can be used as the calcium nutritious supplementary pharmaceutical, though calcium content less than 30% is in the present invention participated in organic metabolism directly after it gets into cell, can reach the effect of fat-reducing and not exist influences hepatic and renal function, has no side effect.
Add mixed vitamin and mixed mineral matter among this embodiment tablet B and can improve overweight people's glycometabolism, fat metabolism and hormone metabolism disorder, and then on the basis of correcting whole metabolic disorder, bring into play the effect of Weight-reducing and lipid-lowering.
The gamma-Linolenic acid that adds among this embodiment tablet B is one of essential fatty acid with extensive physiologically active and obviously pharmacological action of forming each tissue biological's membrane structure of human body; Absorption through reducing exogenous lipid and endogenous lipid synthetic; Promote the transhipment and the drainage of lipid, regulate the effect that fat metabolism realizes lipopenicillinase and fat-reducing.
The specific embodiment two: the difference of this embodiment and the specific embodiment one is: tablet A is made up of 12.0%～18.0% chitosan, 28.0%～32.0% l-cn, 0.02%～0.04% pyridine acid chrome, 28.0%～32.0% CALCIUM PYRUVIC and the auxiliary material of surplus by weight percentage.Other is identical with the specific embodiment one.
The specific embodiment three: the difference of this embodiment and the specific embodiment one is: tablet A is made up of 15.0% chitosan, 30.0% l-cn, 0.03% pyridine acid chrome, 30.0% CALCIUM PYRUVIC and the auxiliary material of surplus by weight percentage.Other is identical with the specific embodiment one.
The specific embodiment four: this embodiment with the difference of the specific embodiment one is: the auxiliary material among the tablet A is calcium monohydrogen phosphate, dolomol, sorbierite, aspartame and superfine silica gel powder.Other is identical with the specific embodiment one.
The specific embodiment five: the difference of this embodiment and the specific embodiment one is: tablet B is made up of 5.0%～7.0% mixed vitamin, 32.0%～38.0% mixed mineral matter, 32.0%～38.0% leukotrienes and the auxiliary material of surplus by weight percentage.Other is identical with the specific embodiment one.
The specific embodiment six: the difference of this embodiment and the specific embodiment one is: tablet B is made up of 6.0% mixed vitamin, 35.0% mixed mineral matter, 35.0% leukotrienes and the auxiliary material of surplus by weight percentage.Other is identical with the specific embodiment one.
The specific embodiment seven: this embodiment with the difference of the specific embodiment one is: the content of vitamin A is that the content of 164～263 μ g/g, bata-carotene is 0.3～1.0mg/g, Cobastab in the mixed vitamin among the tablet B
1Content be 0.3～0.6mg/g, Cobastab
2Content be 0.3～0.6mg/g, Cobastab
6Content be that 0.3～0.6mg/g, ascorbic content are 10.0～30.0mg/g, Cobastab
12Content be that the content of 0.5～2.0 μ g/g, vitamin D is that the content of 1.0～3.0 μ g/g, vitamin E is that the content of 2.0～7.0mg/g, biotin is that the content of 5.0～10.0 μ g/g, folic acid is that the content of 60.0～131.0 μ g/g, nicotinic acid is that the content of 3.0～4.9mg/g, pantothenic acid is 1.0～3.0mg/g.Other is identical with the specific embodiment one.
Mixed vitamin can participate in improving overweight people's metabolic disorder in this embodiment.
The specific embodiment eight: the difference of this embodiment and the specific embodiment one is: among the tablet B in the mixed mineral matter content of zinc be that the content of 2.0～5.0mg/g, potassium is that the content of 10.0～30.0mg/g, copper is that the content of 0.2～0.49mg/g, manganese is that the content of 0.3～0.9mg/g, iodine is that the content of 30.0～60.0 μ g/g, iron is that the content of 4.0～6.5mg/g, selenium is that the content of 6.0～10.0 μ g/g, magnesium is that the content of 60～98mg/g, molybdenum is 6.0～10.0 μ g/g.Other is identical with the specific embodiment one.
Zinc in this embodiment in the mixed mineral matter will the phosphorylation process of tyrosine acceptor have been brought into play the sensitiveness that potential effect also can be strengthened insulin in insulin signaling transduction process, promote the utilization of peripheral tissues to glucose; Iron can significantly reduce the body fat content of obese individuals and strengthen its lean body mass; Magnesium is of value to the raising of beta Cell of islet respond and insulin active.
The specific embodiment nine: this embodiment with the difference of the specific embodiment one is: the auxiliary material among the tablet B is calcium monohydrogen phosphate, superfine silica gel powder, dolomol, aspartame and flavoring pineapple essence.Other is identical with the specific embodiment one.
The specific embodiment ten: this embodiment with the difference of the specific embodiment one is: linolenic mass concentration is 10% among the tablet B.Other is identical with the specific embodiment one.
The specific embodiment 11: this embodiment health products for reducing fat is made up of 1: 1 tablet A and tablet B by mass percentage; Wherein tablet A is made up of 15.0% chitosan, 30.0% l-cn, 0.05% pyridine acid chrome, 30.0% CALCIUM PYRUVIC and the auxiliary material of surplus by weight percentage; Tablet B is made up of 6.0% mixed vitamin, 35.0% mixed mineral matter, 35.0% leukotrienes and the auxiliary material of surplus by weight percentage.
With this implement resulting tablet A by every day dose be 2～4g/ days people dosage every day breakfast, lunch and dinner temperature half an hour ante cibum boiling water take; With this implement resulting tablet B by every day dose be that the temperature boiling water is taken continuous 45 days half an hour after every day breakfast, lunch and dinner for 2～4g/ days people's dosage.
Adopt double-blind study that experimenter crowd is divided into test-meal group (crowd of edible this product in a manner described) and control group (crowd of edible placebo) at random, carry out the fat-reducing effect test.
Table 1 is the basic document of test-meal group and control group.
Table 1
| Project | The test-meal group | Control group |
| The example number | 50 | 50 |
| Man/woman | 24/26 | 23/27 |
| Age (year) | 43.33±8.42 | 43.36±10.72 ※ |
| The course of disease (year) | 10.27±3.79 | 10.55±3.98 ※ |
| Body weight (kilogram) | 77.83±8.27 | 77.35±9.73 ※ |
| Body mass index (%) | 29.40±3.65 | 29.03±2.73 ※ |
| Fat percentage (%) | 34.58±4.90 | 34.85±4.65 ※ |
Contrast between the ※ group: P＞0.05.
From table 1, can find out two groups of patient ages, the course of disease, body weight, body mass index and equal no significant differences of fatty percentage (P＞0.05) before the test-meal, have comparativity, the data that record will have reliability and near True Data.
Table 2 is the (X ± SD) show of changes of weight before and after the test-meal.
Table 2
| Divide into groups | Body weight (kg) before the test-meal | Body weight after the test-meal (kg) | Difference |
| The test-meal group | 77.83±8.27 | 74.66±8.09 ＊※ | -3.17±1.56 |
| Control group | 77.35±9.73 | 77.08±9.74 | -0.28±1.24 |
Compare between test front and back self and group: * own control P＜0.05 contrasts P＜0.05 between the ※ group.
Can find out from table 2 that the test-meal group test forebody-afterbody method of double differences is different has a conspicuousness (P＜0.05), the weight average 3.17 ± 1.56Kg that descends; Test back test-meal group body weight and control group comparing difference have conspicuousness (P＜0.05), prove absolutely that given the test agent has the effect that reduces body weight.
Table 3 changes (X ± SD) show for test-meal forebody-afterbody fat mass.
Table 3
| Divide into groups | Fat mass (kg) before the test-meal | Fat mass after the test-meal (kg) | Difference |
| The test-meal group | 27.36±5.87 | 24.52±4.41 ＊※ | -2.83±1.19 |
| Control group | 27.03±4.97 | 27.26±5.29 | 0.24±1.36 |
Compare between test front and back self and group: * own control P＜0.05 contrasts P＜0.05 between the ※ group.
Can find out that from table 3 test-meal group test forebody-afterbody fat mass difference has conspicuousness (P＜0.05), the body fat amount 2.83 ± 1.19Kg that on average descends; Test back test-meal group body fat amount and control group comparing difference have conspicuousness (P＜0.05), explain that given the test agent has the effect that reduces the body fat amount.
Table 4 is the (X ± SD) show of fatty percentage change before and after the test-meal.
Table 4
| Divide into groups | Fatty percentage (%) before the test-meal | Fatty percentage (%) after the test-meal | Difference |
| The test-meal group | 34.58±3.90 | 31.27±3.79 ＊※ | -3.31±1.59 |
| Control group | 34.85±4.65 | 34.93±4.27 | 0.09±1.04 |
Compare between test front and back self and group: * own control P＜0.05 contrasts P＜0.05 between the ※ group.
Fatty percentage difference has conspicuousness (P＜0.05) before and after from table 4, can finding out the test of test-meal group, on average descends 3.31 ± 1.59%; Test back test-meal group body fat percentage and control group comparing difference have conspicuousness (P＜0.05), explain that given the test agent has the fatty percentile effect of reduction.
Table 5 changes (X ± SD) for the test-meal front and back waist.
Table 5
| Divide into groups | Waistline (cm) before the test-meal | Waistline after the test-meal (cm) | Difference |
| The test-meal group | 94.21±8.11 | 90.03±9.48 ＊※ | -4.18±3.00 |
| Control group | 94.06±8.49 | 94.53±9.33 | 0.46±1.54 |
Compare between test front and back self and group: * own control P＜0.05 contrasts P＜0.05 between the ※ group.
Can find out that from table 5 test-meal group test front and back waist difference has conspicuousness (P＜0.05), waistline decreased average 4.18 ± 3.00cm; Test back test-meal group waistline and control group comparing difference have conspicuousness (P＜0.05), explain that given the test agent has the effect that reduces waistline.
Table 6 changes (X ± SD) show for hip circumference before and after the test-meal.
Table 6
| Divide into groups | Test-meal front hip circumference (cm) | Hip circumference after the test-meal (cm) | Difference |
| The test-meal group | 105.99±8.74 | 103.81±9.13 | -2.18±3.47 |
| Control group | 105.86±5.02 | 105.02±5.09 | -0.84±2.46 |
After can finding out test-meal group test from table 6, hip circumference has reduced by 2.18 ± 3.47cm.
Table 7 changes (X ± SD) show for right angulus inferior scapulae subcutaneous fat thickness before and after the test-meal.
Table 7
| Divide into groups | Right angulus inferior scapulae subcutaneous fat thickness (mm) before the test-meal | Right angulus inferior scapulae subcutaneous fat thickness (mm) after the test-meal | Difference |
| The test-meal group | 24.25±7.50 | 20.97±5.52 ＊※ | -3.28±2.89 |
| Control group | 25.14±6.99 | 25.85±9.21 | 0.71±3.83 |
Compare between test front and back self and group: * own control P＜0.05 contrasts P＜0.01 between the ※ group.
Right angulus inferior scapulae subcutaneous fat thickness difference has conspicuousness (P＜0.05), decreased average 3.28 ± 2.89mm before and after from table 7, can finding out the test of test-meal group; Test back test-meal group and control group comparing difference have conspicuousness (P＜0.01), explain that given the test agent has the effect that reduces right angulus inferior scapulae subcutaneous fat.
Table 8 changes (X ± SD) show for the other 3cm of right navel place subcutaneous fat thickness before and after the test-meal.
Table 8
| Divide into groups | The other 3cm place's subcutaneous fat thickness (mm) of navel before the test-meal | The other 3cm place's subcutaneous fat thickness (mm) of test-meal posterior umbilicus | Difference |
| The test-meal group | ?32.34±8.50 | 27.43±8.38 ＊※ | -4.91±1.46 |
| Control group | ?32.20±8.04 | 32.04±10.68 | -0.17±1.21 |
Compare between test front and back self and group: * own control P＜0.01 contrasts P＜0.05 between the ※ group.
The other 3cm subcutaneous fat thickness of right navel difference has conspicuousness (P＜0.01), decreased average 4.91 ± 1.46mm before and after from table 8, can finding out the test of test-meal group; Test back test-meal group and control group comparing difference have conspicuousness (P＜0.05), explain that given the test agent has the effect that reduces the other subcutaneous fat of right navel.
Table 9 changes (X ± SD) show for right anterior superior spine subcutaneous fat thickness before and after the test-meal.
Table 9
| Divide into groups | Right anterior superior spine subcutaneous fat thickness (mm) before the test-meal | Right anterior superior spine subcutaneous fat thickness (mm) after the test-meal | Difference |
| The test-meal group | 29.67±5.66 | 25.25±7.74 ＊※ | -4.41±2.95 |
| Control group | 29.26±7.15 | 28.28±5.06 | -0.98±1.62 |
Compare between test front and back self and group: * own control P＜0.01 contrasts P＜0.05 between the ※ group.
Right anterior superior spine subcutaneous fat thickness difference has conspicuousness (P＜0.01), decreased average 4.41 ± 2.95mm before and after from table 9, can finding out the test of test-meal group; Test back test-meal group and control group comparing difference have conspicuousness (P＜0.05), explain that given the test agent has the effect that reduces right anterior superior spine subcutaneous fat.
Table 10 is the doing well,improving information slip of hidrosis before and after the test-meal, constipation and lassitude and weak.
Table 10
Can find out that from table 10 the efficient of the hidrosis of test-meal group, constipation and lassitude and weak is respectively 21.43%; 60.00% and 80.95%, the efficient of control group is respectively 11.54%, 16.67% and 27.27%; The test-meal group is compared with control group, and symptom obviously improves.
Table 11 changes (X ± SD) show for maximal oxygen uptake before and after the test-meal.
Table 11
Compare between maximal oxygen uptake self and group before and after the test-meal: P＞0.05.
Can find out that from table 11 two groups of experimenters test the front and back maximal oxygen uptake, no matter self relatively still compares difference that there are no significant (P＞0.05) between group.Before and after test-meal is described the ability to take oxygen in the human body is not had to change basically.
Table 12 compares (X ± SD) show for meals heat before and after the test-meal.
Table 12
Compare between meals heat self and group before and after the test-meal: P＞0.05.
Can find out that from table 12 two groups of experimenters test front and back meals heat and take in, no matter self relatively still compares difference that there are no significant (P＞0.05) between group.Explain that test-meal people from front and back obviously do not change the intake of food.
Table 13 changes relatively (X ± SD) show for blood, urine and stool routine examination safety indexes before and after the test-meal.
Table 13
Above-mentioned each item index is all in normal range (NR) before and after from table 13, can finding out test.
Table 14 is that test-meal front and back heart rate and blood pressure compare (X ± SD) show.
Table 14
Can find out that from table 14 test-meal front and back heart rate and blood pressure index are all in normal range (NR).
Equal no abnormality seen such as spirit, sleep, diet, stool and urine before and after experimenter's test-meal.
The hyperlipemia crowd of complication such as no severe cardiac, liver, kidney that will be 18～65 years old the age is as the experimenter; , as control group, two groups of experimenters are kept carrying out under equal diet and the moving condition lipid-lowering effect test as the test-meal group with the crowd of the edible resulting Weight-lossing hypolipemic medicine of the present invention with the crowd of edible placebo.
Table 15 is the basic document of two groups of tests.
Table 15
| Project | Control group | The test-meal group |
| The example number | 52 | 51 |
| Man/woman | 26/26 | 24/27 |
| Age (year) | 45.56±4.65 | 43.46±8.10 |
| Cholesterol (mmol/L) | 6.42±1.21 | 6.54±1.08 |
| Triglycerides (mmol/L) | 2.34±0.86 | 2.47±0.97 |
Test all no significant differences (P＞0.05) such as preceding two groups of patient ages, blood lipid level, have comparativity.
Table 16 detects index (X ± SD) show for hematology before and after the test-meal.
Table 16
The experimenter passes through routine blood test, blood biochemistry index, stool and urine routine inspection result all in normal range (NR) before and after from table 16, can finding out test.
Table 17 is that test-meal front and back heart rate and blood pressure compare (X ± SD) show.
Table 17
The experimenter passes through heart rate, blood pressure check result all in normal range (NR) before and after from table 17, can finding out test.
Table 18 changes (X ± SD) show for cholesterol before and after the test-meal.
Table 18
| Group | Example number (n) | Cholesterol (mmol/L) before the test | Test back cholesterol (mmol/L) | Decline percentage (%) | Efficient (%) |
| Control group | ?52 | 6.37±0.47 | 6.33±0.51 | 0.56±4.31 | 7.69 |
| The test-meal group | ?51 | 6.34±0.45 | 5.67±0.47 ＊※ | 10.48±5.11 | 56.86 |
* with before the test compare P=0.000, P＜0.01; ※ and control group compare, P=0.000, P＜0.01.
Cholesterol difference has conspicuousness (P＜0.01) before and after from table 18, can finding out the test of test-meal group; Test back test-meal group cholesterol and control group comparing difference have conspicuousness (P＜0.01), and its percentage that on average descends is 13.11 ± 8.64%, and efficient is 56.86%, explain that given the test agent has the effect that reduces cholesterol.
Table 19 is the variation (X ± SD) show of triglycerides before and after the test-meal.
Table 19
| Group | Example number (n) | Triglycerides (mmol/L) before the test | Test back triglycerides (mmol/L) | Decline percentage (%) | Efficient (%) |
| Control group | ?52 | 2.35±0.71 | 2.27±0.68 | 2.83±12.77 | 26.92 |
| The test-meal group | ?51 | 2.41±0.59 | 1.93±0.52 ＊＊※ | 19.57±8.12 | 66.67 |
* with before the test compare P=0.000, P＜0.01; ※ and control group compare, P=0.005, P＜0.01.
Triglycerides difference has conspicuousness (P＜0.01) before and after from table 19, can finding out the test of test-meal group; Test back test-meal group triglycerides and control group comparing difference have conspicuousness (P＜0.01), and its percentage that on average descends is 25.93 ± 24.82%, and efficient is 66.67%, explain that given the test agent has the effect that reduces triglycerides.
Table 20 is a clinical observation effect comparison sheet.
Table 20
| Group | Example number (n) | Effectively | Invalid | Total effective rate % |
| Control group | ?52 | 6 | 46 | 11.54 |
| The test-meal group | ?51 | 27 | 24 | 52.94 ※ |
※ and control group be χ relatively
2=20.270, P＜0.01.
Find out from table 20 at the test-meal given the test agent after 45 days that test-meal group clinical observation total effective rate and control group comparing difference have conspicuousness (P＜0.01), explain that given the test agent has obvious effects to the reducing blood lipid symptom.
Claims (3)
1. health products for reducing fat is characterized in that health products for reducing fat forms by the tablet A and the tablet B of mass ratio by 1: 1; Wherein tablet A is made up of 10.0%～20.0% chitosan, 25.0%～35.0% l-cn, 0.01%～0.06% pyridine acid chrome, 25.0%～35.0% CALCIUM PYRUVIC and the auxiliary material of surplus by weight percentage; Tablet B is made up of 4.0%～8.0% mixed vitamin, 30.0%～40.0% mixed mineral matter, 30.0%～40.0% leukotrienes and the auxiliary material of surplus by weight percentage; Wherein the content of vitamin A is that the content of 164～263 μ g/g, bata-carotene is 0.3～1.0mg/g, Cobastab in the mixed vitamin among the tablet B
1Content be 0.3～0.6mg/g, Cobastab
2Content be 0.3～0.6mg/g, Cobastab
6Content be that 0.3～0.6mg/g, ascorbic content are 10.0～30.0mg/g, Cobastab
12Content be that the content of 0.5～2.0 μ g/g, vitamin D is that the content of 1.0～3.0 μ g/g, vitamin E is that the content of 2.0～7.0mg/g, biotin is that the content of 5.0～10.0 μ g/g, folic acid is that the content of 60.0～131.0 μ g/g, nicotinic acid is that the content of 3.0～4.9mg/g, pantothenic acid is 1.0～3.0mg/g; Among the tablet B in the mixed mineral matter content of zinc be that the content of 2.0～5.0mg/g, potassium is that the content of 10.0～30.0mg/g, copper is that the content of 0.2～0.49mg/g, manganese is that the content of 0.3～0.9mg/g, iodine is that the content of 30.0～60.0 μ g/g, iron is that the content of 4.0～6.5mg/g, selenium is that the content of 6.0～10.0 μ g/g, magnesium is that the content of 60～98mg/g, molybdenum is 6.0～10.0 μ g/g.
2. health products for reducing fat according to claim 1 is characterized in that tablet A is made up of 12.0%～18.0% chitosan, 28.0%～32.0% l-cn, 0.02%～0.04% pyridine acid chrome, 28.0%～32.0% CALCIUM PYRUVIC and the auxiliary material of surplus by weight percentage.
3. health products for reducing fat according to claim 1 is characterized in that tablet B is made up of 5.0%～7.0% mixed vitamin, 32.0%～38.0% mixed mineral matter, 32.0%～38.0% leukotrienes and the auxiliary material of surplus by weight percentage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100649492A CN101322554B (en) | 2008-07-18 | 2008-07-18 | Health products for reducing fat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100649492A CN101322554B (en) | 2008-07-18 | 2008-07-18 | Health products for reducing fat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101322554A CN101322554A (en) | 2008-12-17 |
| CN101322554B true CN101322554B (en) | 2012-07-04 |
Family
ID=40186387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100649492A Active CN101322554B (en) | 2008-07-18 | 2008-07-18 | Health products for reducing fat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101322554B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102115717B (en) * | 2009-12-31 | 2013-07-10 | 安琪酵母股份有限公司 | Low nucleic acid yeast product, preparation method thereof and weight-reducing product comprising same |
| US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
| US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
| CN103349278A (en) * | 2013-06-14 | 2013-10-16 | 芜湖市诺康生物科技有限公司 | Vitamin mineral tablets |
-
2008
- 2008-07-18 CN CN2008100649492A patent/CN101322554B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101322554A (en) | 2008-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Clarke et al. | Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects | |
| Jenkins et al. | Dietary fibres, fibre analogues, and glucose tolerance: importance of viscosity. | |
| Bui et al. | Pre-germinated brown rice reduced both blood glucose concentration and body weight in Vietnamese women with impaired glucose tolerance | |
| Kotler et al. | Body mass repletion during ganciclovir treatment of cytomegalovirus infections in patients with acquired immunodeficiency syndrome | |
| CN101248900A (en) | Novel solid sport drink medicinal granules | |
| CN107951015A (en) | Full nutrient formulation powder and preparation method thereof | |
| US20210085712A1 (en) | Functional food | |
| CN101322554B (en) | Health products for reducing fat | |
| CN1820647A (en) | Nutrition powder for increasing memory | |
| Vojtková et al. | Hypovitaminosis D in children with type 1 diabetes mellitus and its influence on biochemical and densitometric parameters | |
| Nishioka et al. | The concept of aggressive nutrition therapy and clinical indication: A position paper | |
| Berryman et al. | Effects in young men consuming restricted quantities of B-complex vitamins and protein, and changes associated with supplementation | |
| Hoffman | Diet in the elderly: Needs and risks | |
| Elia | The effects of nitrogen and energy intake on the metabolism of normal, depleted and injured man: considerations for practical nutritional support | |
| Klein | A primer of nutritional support for gastroenterologists | |
| CN108208798A (en) | Full nutrient formulation liquid and preparation method thereof | |
| Elia | Principles of Clinical Nutrition: Contrasting the practice of nutrition in health and disease | |
| EP2744353A1 (en) | Method of transforming a meal | |
| CN103082167A (en) | Composite enteral nutrition applicable to AIDS patients | |
| US20100278799A1 (en) | Composition for Improving Nutritional Status, Reducing Frequency of Fever and/or Increasing Immunocompetence of the Elderly | |
| WO2008140064A1 (en) | Nutrient composition for prevention and amelioration of lifestyle-related disease | |
| US6932987B1 (en) | Chemical composition and method for enhancing metabolism | |
| CN101433329A (en) | Nutritive composition with health-care function | |
| Ikem et al. | A controlled comparison of the effect of a high fiber diet on the glycemic and lipid profile of Nigerian clinic patients with type 2 diabetes | |
| Kaminski et al. | Metabolic and nutritional support of the intensive care patient: Ascending the learning curve |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: HARBIN MEDICAL UNIVERSITY Free format text: FORMER OWNER: SUN CHANGHAO Effective date: 20120514 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Sun Changhao Inventor after: Li Ying Inventor after: Niu Yucun Inventor after: Wang Cheng Inventor after: Wen Ying Inventor after: Liu Li Inventor after: Kang Zhen Inventor before: Sun Changhao Inventor before: Li Ying Inventor before: Wang Cheng Inventor before: Wen Ying Inventor before: Liu Li Inventor before: Kang Zhen Inventor before: Niu Yucun |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: SUN CHANGHAO LI YING WANG CHENG WEN YIN LIU LI KANG ZHEN NIU YUCUN TO: SUNCHANGHAO LI YING NIU YUCUN WANG CHENG WEN YIN LIU LI KANG ZHEN Free format text: CORRECT: ADDRESS; FROM: 150081 HARBIN, HEILONGJIANG PROVINCE TO: 150001 HARBIN, HEILONGJIANG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20120514 Address after: 150001 No. 157 health Road, Nangang District, Heilongjiang, Harbin Applicant after: Harbin Medical University Address before: Nangang District of Heilongjiang city in Harbin Province Health Road 150081 No. 157 Harbin Medical University School of public health Applicant before: Sun Changhao |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |